Treatment response in CML   -   Chronic Myeloid Leukemia

Types of responses:
​
Hematologic response (HR)
Complete hematologic response (CHR)
Major cytogenetic response (MCR or MCyR)
Complete cytogenetic response (CCR or CCyR)
Major molecular response  (MMR)
Complete molecular response (CMR)

    
​

Reduction of white cells
Normal count of white cells
1 - 35% Ph+ cells
No Ph+ cells
BCR-ABL IS ≤ 0.10%
no BCR-ABL detectible

SITES

Molecular response: a measure of treatment success in Philadelphia chromosome-positive  Chronic Myeloid Leukemia (Ph+ CML)  by CMLadvocates

Monitoring and test by The National CML Society

Response/Remission by The National CML Society

VIDEOS

Mechanisms of TKI resistance
October 9, 2017, European Society for Medical Oncology

CML molecular monitoring: Practical advice        
April 15, 2016, ImedexCME

Resistant Chronic Myeloid Leukemia
June 19, 2015, Leukemia & Lymphoma Society

ARTICLES

BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase
July 21, 2015, Leukemia

Dynamics Of Chronic Myeloid Leukemia Response To Dasatinib, Nilotinib, And High-Dose Imatinib
November 2014, Haematologica

Molecular response in CML: where is the bar? | Blood Journal
2014, Blood Journal

Monitoring the Response to Tyrosine Kinase Inhibitor (TKI) Treatment in Chronic Myeloid Leukemia (CML)
2014, NCBI

European LeukemiaNet Recommendations for Management of Chronic Myeloid Leukemia
2013, PubMed

Major Molecular Response in CML Patients Treated with Tyrosine Kinase Inhibitors: The Paradigm for Monitoring Targeted Cancer Therapy
June 21, 2010, The Oncologist

Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia
May 20, 2008,  Blood Journal